Inovio Pharmaceuticals, Inc. (INO)
NASDAQ·Healthcare·Biotechnology
$1.15
-1.71%
Mkt Cap $62.70M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 12, 2026 | $333.33K | — | — | -$0.37 | $0.31 | +183.78% | — | — |
| Q4 2025 Nov 10, 2025 | — | — | — | -$0.51 | -$0.44 | +13.73% | — | — |
| Q3 2025 Aug 12, 2025 | $10.00K | — | — | -$0.63 | -$0.61 | +3.17% | — | — |
| Q2 2025 May 13, 2025 | $10.00K | $65.34K | +553.43% | -$0.74 | -$0.51 | +31.08% | — | — |
| Q1 2025 Mar 18, 2025 | $50.00K | $116.99K | +133.99% | -$0.87 | -$0.69 | +20.69% | — | — |
| Q4 2024 Nov 14, 2024 | $30.00K | — | — | -$1.20 | -$0.89 | +25.83% | — | — |
| Q3 2024 Aug 8, 2024 | $120.00K | $100.76K | -16.03% | -$1.15 | -$1.19 | -3.48% | — | — |
| Q2 2024 May 13, 2024 | $150.00K | — | — | -$1.08 | -$1.31 | -21.30% | — | — |
| Q1 2024 Mar 6, 2024 | $340.00K | $102.65K | -69.81% | -$1.27 | -$1.12 | +11.81% | — | — |
| Q4 2023 Nov 9, 2023 | $110.00K | $388.45K | +253.13% | -$1.56 | -$1.08 | +30.77% | — | — |
| Q3 2023 Aug 9, 2023 | $260.00K | $225.97K | -13.09% | -$1.68 | -$1.56 | +7.14% | — | — |
| Q2 2023 May 10, 2023 | $270.00K | $114.94K | -57.43% | -$1.68 | -$1.92 | -14.29% | — | — |
| Q1 2023 Mar 1, 2023 | $339.28K | $124.67K | -63.26% | -$1.92 | -$2.52 | -31.25% | — | — |
| Q4 2022 Nov 8, 2022 | $623.17K | $9.15M | +1368.97% | -$3.48 | -$1.80 | +48.28% | — | — |
| Q3 2022 Aug 9, 2022 | $529.00K | $784.39K | +48.28% | -$3.60 | -$5.52 | -53.33% | — | — |
| Q2 2022 May 10, 2022 | $773.00K | $199.07K | -74.25% | -$3.36 | -$4.32 | -28.57% | — | — |
| Q1 2022 Mar 1, 2022 | $2.52M | $839.12K | -66.72% | -$3.96 | -$6.00 | -51.52% | — | — |
| Q4 2021 Nov 9, 2021 | $970.00K | $291.70K | -69.93% | -$3.96 | -$3.48 | +12.12% | — | — |
| Q3 2021 Aug 9, 2021 | $273.00K | $272.82K | -0.06% | -$3.00 | -$4.68 | -56.00% | — | — |
| Q2 2021 May 10, 2021 | $306.17K | $371.12K | +21.21% | -$2.16 | -$3.24 | -50.00% | — | — |